At primary analysis, median MFS was prolonged by 22 months in the darolutamide arm as compared with the PBO arm with a HR of 0.41 and a highly significant p -value of 0.003.
← all excerpts
Prostate cancer-highlights from American Society of Clinical Oncology virtual meeting 2020.
1
—
—